臨床検査64巻12号

2020年12月発行

今月の特集1 血栓止血学のトピックス—求められる検査の原点と進化

凝固波形解析の概要とその応用

著者： 松本智子¹

所属機関： ¹天理医療大学臨床検査学科

ページ範囲：P.1402 - P.1408

Point

●凝固波形解析（CWA）では，フィブリン析出までの時間のみならず，それぞれの微分波形を用いて，最大凝固速度や最大凝固加速度など，多様な情報を得ることができる．

●自動凝固分析装置を用いたCWAは検査室で行うことができる．先天性血友病Aをはじめ，後天性血友病A（AHA）や抗リン脂質抗体症候群（APS）など，凝固異常症の鑑別に有用である．

●凝固線溶波形解析（CFWA）はCWAを応用した方法である．フィブリン形成から溶解までの一連の反応を観察でき，凝固・線溶異常症の早期診断に貢献できる．

参考文献

1）小川覚，岡林志帆子：大量出血における止血機能モニタリング．Thromb Med　6：17-25，2016

2）Matsumoto T, Nogami K, Ogiwara K, et al：A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol　90：576-582，2009

3）Shima M, Matsumoto T, Fukuda K, et al：The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost　87：436-441，2002

4）Shima M, Thachil J, Nair SC, et al：Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost　11：1417-1420，2013

5）Katayama H, Matsumoto T, Wada H, et al：An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform. Clin Appl Thromb Hemost　24：1170-1176，2018

distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. Haemophilia　23：e427-e435，2017

7）Matsumoto T, Nogami K, Shima M：A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. Int J Hematol　105：174-183，2017

8）Matsumoto T, Nogami K, Ogiwara K, et al：A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost　107：288-301，2012

9）Matsumoto T, Nogami K, Shima M：Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors. J Thromb Haemost　12：1503-1512，2014

10）Hasegawa M, Wada H, Tone S, et al：Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform. Int J Lab Hematol　40：49-55，2018

11）Wakui M, Fujimori Y, Katagiri H, et al：Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis. J Clin Pathol　72：244-250，2019

12）Matsumoto T, Nogami K, Shima M：Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost　110：761-768，2013

13）Nogami K, Matsumoto T, Sasai K, et al：A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. Br J Haematol　187：518-529，2019

14）野上恵嗣，中島由翔：血友病と線溶系．日血栓止血会誌　31：366-372，2020

-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood　100：2522-2529，2002

16）Onishi T, Nogami K, Ishihara T：A Pathological Clarification of Sepsis-Associated Disseminated Intravascular Coagulation Based on Comprehensive Coagulation and Fibrinolysis Function．Thromb Haemost　120：1257-1269，2020

17）Oka S, Wakui M, Fujimori Y, et al：Application of clot-fibrinolysis waveform analysis to assessment of in vitro effects of direct oral anticoagulants on fibrinolysis. Int J Lab Hematol　42：292-298，2020